

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

POSITIVE PROFIT ALERT

This announcement is made by Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of directors of the Company (the “**Board**”) would like to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that the Group’s profit attributable to the owners of the parent for the six months ended 30 June 2021 is expected to increase by over 500% as compared to the same period last year (profit attributable to the owners of the parent (restated) for the same period last year was RMB1,240.61 million). The substantial year-on-year increase in profit attributable to the owners of the parent was mainly attributable to: (1) the satisfactory performance of the Group’s principal business. During the period, sales of new products and high margin products increased, resulting in a notable year-on-year increase in both revenue and gross profit margin; and (2) the strong financial performance of an associate; thus the Group’s share of profits and losses of associates and a joint venture increased substantially during the period.

The Company is still in the process of finalizing its results for the six months ended 30 June 2021. The financial information contained in this announcement is solely based on a preliminary assessment by the management of the Company on the Company’s existing consolidated management accounts and is subject to finalization and adjustment, if any. Details of the financial information will be disclosed in the interim results announcement to be published by the Company on 31 August 2021.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 18 August 2021

As at the date of this announcement, the Board of the Company comprises nine Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Mr. Li Kwok Tung Donald.